Table 2. Reasons of withdrawal from sorafenib^*.

	Total (n = 652)	Sorafenib (n = 291)	TACE followed by sorafenib (n = 236)	TACE combined with sorafenib (n = 125)	P value
Disease progression [n (%)]	421 (64.6)	193 (66.4)	163 (68.9)	65 (52.3)	0.10
Adverse drug reactions [n (%)]	87 (13.3)	38 (13.2)	22 (9.3)	27 (21.5)	0.06
Worsening liver function or death [n (%)]	6 (0.9)	4 (1.3)	0 (0.0)	2 (1.5)	0.87
Physicians' decision [n (%)]	21 (3.2)	6 (2.0)	6 (2.5)	9 (7.2)	0.08
Economic issue [n (%)]	6 (0.9)	0 (0.0)	6 (2.5)	0 (0.0)	0.07
Unknown (including loss of follow-up) [n (%)]	69 (10.6)	28 (9.6)	27 (11.5)	14 (10.8)	0.92

^*Data are presented as means ± standard deviations.

TACE, transarterial chemoembolization